Baillie Gifford & CO Xencor Inc Transaction History

Baillie Gifford & CO

$131 Billion
Q3 2024

A detailed history of Baillie Gifford & CO transactions in Xencor Inc stock. As of the latest transaction made, Baillie Gifford & CO holds 23,204 shares of XNCR stock, worth $447,837. This represents 0.0% of its overall portfolio holdings.

Number of Shares

23,204

Previous 23,530 1.39%

Holding current value

$447,837

Previous $445,000 4.72%

% of portfolio

0.0%

Previous 0.0%

14 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 05, 2024	SELL	$15.7 - $21.65 $5,118 - $7,057	-326 Reduced 1.39%	23,204 $466,000
Q2 2024 Jul 25, 2024	BUY	$18.21 - $24.5 $13,548 - $18,228	744 Added 3.27%	23,530 $445,000
Q1 2024 May 01, 2024	SELL	$18.65 - $26.52 $153,284 - $217,967	-8,219 Reduced 26.51%	22,786 $504,000
Q4 2023 Jan 26, 2024	SELL	$16.53 - $21.42 $5,173 - $6,704	-313 Reduced 1.0%	31,005 $658,000
Q2 2023 Jul 28, 2023	SELL	$24.77 - $29.9 $10,799 - $13,036	-436 Reduced 1.37%	31,318 $782,000
Q1 2023 May 03, 2023	SELL	$25.95 - $36.95 $7,810 - $11,121	-301 Reduced 0.94%	31,754 $885,000
Q3 2022 Oct 27, 2022	BUY	$24.62 - $32.44 $34,418 - $45,351	1,398 Added 4.56%	32,055 $833,000
Q2 2022 Aug 08, 2022	SELL	$19.74 - $29.01 $27,241 - $40,033	-1,380 Reduced 4.31%	30,657 $839,000
Q1 2022 May 05, 2022	BUY	$26.68 - $41.63 $72,836 - $113,649	2,730 Added 9.32%	32,037 $855,000
Q4 2021 Jan 20, 2022	BUY	$33.67 - $43.44 $944,376 - $1.22 Million	28,048 Added 2227.8%	29,307 $1.18 Million
Q3 2021 Oct 19, 2021	BUY	$30.65 - $35.68 $10,880 - $12,666	355 Added 39.27%	1,259 $41,000
Q2 2021 Aug 02, 2021	BUY	$34.33 - $44.68 $16,238 - $21,133	473 Added 109.74%	904 $31,000
Q1 2021 May 06, 2021	SELL	$40.81 - $53.88 $734 - $969	-18 Reduced 4.01%	431 $19,000
Q4 2020 Feb 10, 2021	BUY	$36.63 - $47.63 $16,446 - $21,385	449 New	449 $20,000

Others Institutions Holding XNCR

# of Institutions

216

Shares Held

71.5M

Call Options Held

2.5K

Put Options Held

7.9K

View Full List

About Xencor Inc

Ticker XNCR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 59,698,100
Market Cap $1.15B
Description
Xencor, Inc., a clinical stage biopharmaceutical company, focuses on the discovery and development of engineered monoclonal antibody and cytokine therapeutics to treat patients with cancer and autoimmune diseases. The company provides Sotrovimab that targets the SARS-CoV-2 virus; Ultomiris for the treatment of patients with paroxysmal nocturnal ...

More about XNCR

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Baillie Gifford & CO, based on Form 13F filings with the SEC.

News

Stay updated on Baillie Gifford & CO with notifications on news.

Account

Baillie Gifford & CO Xencor Inc Transaction History